Intratumoral immunocytokine treatment results in enhanced antitumor effects

Cancer Immunology, Immunotherapy

Volumn 57, Issue 12, 2008, Pages 1891-1902

  Johnson, Erik E ^a   Lum, Hillary D ^a   Rakhmilevich, Alexander L ^a,b   Schmidt, Brian E ^a   Furlong, Meghan ^a   Buhtoiarov, Ilia N ^a   Hank, Jacquelyn A ^a,b   Raubitschek, Andrew ^c   Colcher, David ^c   Reisfeld, Ralph A ^d   Gillies, Stephen D ^e   Sondel, Paul M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Scripps Research Institute ^*  (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e EMD SERONO INC   (United States)

Author keywords

Hu14.18 IL2; HuKS IL2; Immunocytokine; Intratumoral; Melanoma; Neuroblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY 14 18 INTERLEUKIN 2 FUSION PROTEIN; MONOCLONAL ANTIBODY GCT84 66 INTERLEUKIN 2 IN 111; MONOCLONAL ANTIBODY HUKS INTERLEUKIN 2 FUSION PROTEIN; RECOMBINANT INTERLEUKIN 2; TECIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG RETENTION; FEMALE; GENE EXPRESSION; GENE TARGETING; LOW DRUG DOSE; MELANOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MICE; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 52549117059     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0519-0     Document Type: Article

References (42)

1. U Altenschmidt M Schmidt B Groner W Wels 1997 Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin Int J Cancer 73 1 117 124
2. IN Buhtoiarov H Lum G Berke DM Paulnock PM Sondel AL Rakhmilevich 2005 CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro J Immunol 174 10 6013 6022
3. IN Buhtoiarov HD Lum G Berke PM Sondel AL Rakhmilevich 2006 Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects J Immunol 176 1 309 318
4. NK Cheung H Lazarus FD Miraldi CR Abramowsky S Kallick UM Saarinen T Spitzer SE Strandjord PF Coccia NA Berger 1987 Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma J Clin Oncol 5 9 1430 1440
5. NK Cheung BH Kushner SJ Yeh SM Larson 1994 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study Prog Clin Biol Res 385 319 328
6. O Christ S Seiter S Matzku C Burger M Zoller 2001 Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy Clin Cancer Res 7 4 985 998
7. P Clarke J Mann JF Simpson K Rickard-Dickson FJ Primus 1998 Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy Cancer Res 58 7 1469 1477
8. JP Connor M Felder J Hank J Harter J Gan SD Gillies P Sondel 2004 Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer J Immunother 27 3 211 9
9. CS Dolman BM Mueller HN Lode R Xiang SD Gillies RA Reisfeld 1998 Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clin Cancer Res 4 10 2551 2557
10. SD Gillies EB Reilly KM Lo RA Reisfeld 1992 Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells Proc Natl Acad Sci USA 89 4 1428 1432
11. SD Gillies Y Lan KM Lo M Super J Wesolowski 1999 Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors Cancer Res 59 9 2159 2166
12. SD Gillies Y Lan B Brunkhorst WK Wong Y Li KM Lo 2002 Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer Cancer Immunol Immunother 51 8 449 460
13. C Guiducci CE Di M Parenza M Hitt M Giovarelli P Musiani MP Colombo 2004 Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor J Immunol 172 7 4026 4036
14. R Handgretinger P Baader R Dopfer T Klingebiel P Reuland J Treuner RA Reisfeld D Niethammer 1992 A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a Cancer Immunol Immunother 35 3 199 204
15. JA Hank JE Surfus JC Gan P Jaeger SD Gillies RA Reisfeld PM Sondel 1996 Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD (2) interleukin-2 fusion protein (ch14.18-IL2) Clin Cancer Res 2 12 1951 1959
16. SA Holden Y Lan AM Pardo JS Wesolowski SD Gillies 2001 Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents Clin Cancer Res 7 9 2862 2869
17. H Idani J Matsuoka T Yasuda K Kobayashi N Tanaka 2000 Intra-tumoral injection of doxorubicin (adriamycin) encapsulated in liposome inhibits tumor growth, prolongs survival time and is not associated with local or systemic side effects Int J Cancer 88 4 645 651
18. M Imboden KR Murphy AL Rakhmilevich ZC Neal R Xiang RA Reisfeld SD Gillies PM Sondel 2001 The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy Cancer Res 61 4 1500 1507
19. +T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2 J Immunol 171 10 5051 5063
20. K Kendra J Gan M Ricci J Surfus A Shaker M Super JD Frost A Rakhmilevich JA Hank SD Gillies PM Sondel 1999 Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice Cancer Immunol Immunother 48 5 219 229
21. DM King MR Albertini H Schalch JA Hank J Gan J Surfus D Mahvi JH Schiller T Warner K Kim J Eickhoff K Kendra R Reisfeld SD Gillies P Sondel 2004 Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients J Clin Oncol 22 22 4463 4473
22. YJ Ko GJ Bubley R Weber C Redfern DP Gold L Finke A Kovar T Dahl SD Gillies 2004 Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer J Immunother 27 3 232 239
23. HN Lode R Xiang NM Varki CS Dolman SD Gillies RA Reisfeld 1997 Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow J Natl Cancer Inst 89 21 1586 1594
24. HN Lode R Xiang JC Becker SD Gillies RA Reisfeld 1998 Immunocytokines: a promising approach to cancer immunotherapy Pharmacol Ther 80 3 277 292
25. HN Lode R Xiang T Dreier NM Varki SD Gillies RA Reisfeld 1998 Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood 91 5 1706 1715
26. HD Lum IN Buhtoiarov BE Schmidt G Berke DM Paulnock PM Sondel AL Rakhmilevich 2006 In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages J Leukoc Biol 79 6 1181 1192
27. V Mattijssen LT Balemans PA Steerenberg PH De Mulder 1992 Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors Int J Cancer 51 5 812 817
28. JJ Mule JC Yang RL Afreniere SY Shu SA Rosenberg 1987 Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2 J Immunol 139 1 285 294
29. ZC Neal M Imboden AL Rakhmilevich KM Kim JA Hank J Surfus JR Dixon HN Lode RA Reisfeld SD Gillies PM Sondel 2004 NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy Cancer Immunol Immunother 53 1 41 52
30. ZC Neal JC Yang AL Rakhmilevich IN Buhtoiarov HE Lum M Imboden JA Hank HN Lode RA Reisfeld SD Gillies PM Sondel 2004 Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy Clin Cancer Res 10 14 4839 4847
31. ME Neville RJ Robb MC Popescu 2001 In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2 Cytokine 16 6 239 250
32. K Osenga J Hank M Albertini J Gan A Sternberg R Seeger K Matthay P Reynolds M Krailo P Adamson R Reisfeld S Gillies P Sondel 2004 A phase I trial of immunocytokine HU14.18-IL2 in children with recurrent or refractory neuroblastoma and other GD2 positive malignancies: a study of the children's oncology group J Immunother 27 6 S55 S56
33. KL Osenga JA Hank MR Albertini J Gan AG Sternberg J Eickhoff RC Seeger KK Matthay CP Reynolds C Twist M Krailo PC Adamson RA Reisfeld SD Gillies PM Sondel 2006 A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the children's oncology group Clin Cancer Res 12 6 1750 1759
34. MN Saleh MB Khazaeli RH Wheeler E Dropcho T Liu M Urist DM Miller S Lawson P Dixon CH Russell 1992 Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma Cancer Res 52 16 4342 4347
35. S Sharma CP Karakousis H Takita K Shin SP Brooks 2003 Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors Biotechnol Lett 25 2 149 153
36. PM Sondel JA Hank 1997 Combination therapy with interleukin-2 and antitumor monoclonal antibodies Cancer J Sci Am 3 Suppl 1 S121 S127
37. PM Sondel JA Hank 2001 Antibody-directed, effector cell-mediated tumor destruction Hematol Oncol Clin North Am 15 4 703 721
38. Sondel PM, Gillies SD (2004) Immunocytokines for Cancer Immunotherapy. In: Morse MA, Blay TM, Lyerly HK, (eds). Handbook of Cancer Vaccines. Humana Press, Totowa pp 341-358
39. Sondel PM, Hank JA, Albertini MR, Gillies SD (2007). Novel strategies for cytokine administration via targeting. In: Caligiuri MA, Lotze MT, (eds). Cancer Drug Discovery and Development, Cytokines in the Genesis and Treatment of Cancer. Humana Press, Totowa, pp 399-422
40. SD Voss RJ Robb G Weil-Hillman JA Hank K Sugamura M Tsudo PM Sondel 1990 Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56 + natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding J Exp Med 172 4 1101 1114
41. G Weil-Hillman P Fisch AF Prieve JA Sosman JA Hank PM Sondel 1989 Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens Cancer Res 49 13 3680 3688
42. X Xu P Clarke G Szalai JE Shively LE Williams Y Shyr E Shi FJ Primus 2000 Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein Cancer Res 60 16 4475 4484